Introduction: Gestational diabetes mellitus (GDM) is defined as any degree of glucose intolerance with onset or first recognition during pregnancy. The diagnosis of GDM is made by performing the oral glucose tolerance test (OGTT) in women with risk factors, usually during 24th to 28th week of gestation. The most common used insulin therapy regime is a conventional intensive insulin therapy with four daily doses.
Objective: The aim of our study was to determine the changes in parameters of glycoregulation in GDM patients with different approach to the introduction of insulin therapy.
Methods: Study group consisted of 50 pregnant women divided into two groups depending on the parameters of glycoregulation (glycemic profile and HbA1). Group 1 consisted of pregnant women initially treated with diet only and then, according to glycemic profile and HbA1 profile, in the next few weeks with insulin therapy. Group 2 were pregnant women who were treated with insulin therapy immediately after GDM diagnosis.
Results: There was a statistically significant difference in mean glycemia values in the 60th and 120th minute between the two groups (p = 0.001). There was a difference in mean value of fasting blood and postprandial glucose between the two groups; it was higher in Group 2. There was a statistically significant difference between the two groups in HbA1c value at the beginning (5.1 +/- 0.4% vs. 5.42 +/- 0.43%, p = 0.005) and at the end of therapy (4.87 +/- 0.29% vs. 5.1 +/- 0.39 %, p = 0.018).
Conclusion: Satisfactory glycoregulation was achieved in both studied groups.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.2298/sarh1210583m | DOI Listing |
BMC Complement Med Ther
January 2025
Department of Nutrition, Qazvin University of Medical Sciences, Qazvin, Iran.
Background: It seems that oxidative stress is involved in the occurrence and progression of non-alcoholic fatty liver disease (NAFLD). Considering the antioxidant features of Ellagic acid (EA), this study was designed to assess the effect of EA on some biochemical factors in patients with NAFLD.
Methods: In this clinical trial, 44 patients were selected based on including criteria and randomly received 180 mg of EA per day (n = 22) or placebo (n = 22) for 8 weeks.
Leukemia
January 2025
Department of Pathology, Duke University School of Medicine, Durham, NC, 27710, USA.
Multiple myeloma (MM) remains an incurable hematological malignancy that necessitates the identification of novel therapeutic strategies. Here, we report that intracellular levels of very long chain fatty acids (VLCFAs) control the cytotoxicity of MM chemotherapeutic agents. Inhibition of VLCFA biosynthesis reduced cell death in MM cells caused by the proteasome inhibitor, bortezomib.
View Article and Find Full Text PDFACS Nano
January 2025
Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St Lucia, QLD 4072, Australia.
Type-2-diabetes is a metabolic disorder where misfolding and oligomerization of islet amyloid polypeptide (IAPP) around islet-β cells oligomerizes and participates in the pathology. The oligomeric stage is toxic but transitory and leads to the formation of mature amyloid fibrils. The pathological specifics of mature amyloid fibrils are poorly understood.
View Article and Find Full Text PDFLancet Diabetes Endocrinol
January 2025
Norwich Medical School, University of East Anglia, Norwich, UK; Diabetes and Antenatal Care, Norfolk and Norwich NHS Foundation Trust, Norwich, UK. Electronic address:
Background: Clinical guidelines in the UK and elsewhere do not specifically address hybrid closed loop (HCL) use in the postpartum period when the demands of caring for a newborn are paramount. Our aim was to evaluate the safety and efficacy of HCL use during the first 6 months postpartum compared with standard care.
Methods: In this prespecified extension to a multicentre, randomised controlled trial, pregnant women with type 1 diabetes at nine UK sites were followed up for 6 months postpartum.
PLoS One
January 2025
Faculty of Veterinary Science, Veterinary Clinical Stem Cell and Bioengineering Research Unit, Chulalongkorn University, Bangkok, Thailand.
Potential trend of regenerative treatment for type I diabetes has been introduced for more than a decade. However, the technologies regarding insulin-producing cell (IPC) production and transplantation are still being developed. Here, we propose the potential IPC production protocol employing mouse gingival fibroblast-derived induced pluripotent stem cells (mGF-iPSCs) as a resource and the pre-clinical approved subcutaneous IPC transplantation platform for further clinical confirmation study.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!